Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
32.42
-0.97 (-2.91%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Company Description

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.

It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing’s disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors.

In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity.

The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist.

Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals logo
Country United States
Founded 2008
IPO Date Jul 18, 2018
Industry Biotechnology
Sector Healthcare
Employees 437
CEO R. Struthers

Contact Details

Address:
6055 Lusk Boulevard
San Diego, California 92121
United States
Phone 858 450 6464
Website crinetics.com

Stock Details

Ticker Symbol CRNX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001658247
CUSIP Number 22663K107
ISIN Number US22663K1079
Employer ID 26-3744114
SIC Code 2834

Key Executives

Name Position
Dr. R. Scott Struthers Ph.D. Founder, President, Chief Executive Officer and Director
Dr. Stephen F. Betz Ph.D. Founder and Chief Scientific Officer
Jeff E. Knight Chief Operating Officer
Dr. Alan S. Krasner M.D. Chief Endocrinologist
Tobin C. Schilke Chief Financial Officer
Gayathri Diwakar Head of Investor Relations
Garlan Adams Chief Legal Officer and Corporate Secretary
Adriana Cabre M.B.A. Chief Human Resources Officer
Kevin Capps Head of Intellectual Property
Chris Robillard M.B.A. Chief Business Officer

Latest SEC Filings

Date Type Title
Apr 23, 2025 ARS Filing
Apr 23, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 23, 2025 DEF 14A Other definitive proxy statements
Apr 7, 2025 SCHEDULE 13G/A Filing
Apr 4, 2025 8-K Current Report
Feb 27, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 24, 2025 8-K Current Report
Feb 10, 2025 SCHEDULE 13G/A Filing